Literature DB >> 22499452

Recruitment methods for United States Alzheimer disease prevention trials.

L S Schneider1.   

Abstract

There are no substantially effective treatments or preventatives for Alzheimer disease. The few prevention trials that were undertaken did not shown efficacy for the drugs tested; but, nevertheless, advanced prevention trials methods. We review past recruitment methods and discuss areas for improvement. Improvements in recruitment methods can enhance the likelihood for accurately demonstrating the efficacy of an effective drug. Effective therapeutics to prevent AD await discovery and proof.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22499452     DOI： 10.1007/s12603-012-0011-6

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN： 1279-7707            Impact factor:   4.075


  28 in total

Review 1.  Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life.

Authors:  Brenda L Plassman; John W Williams; James R Burke; Tracey Holsinger; Sophiya Benjamin
Journal:  Ann Intern Med       Date:  2010-06-14       Impact factor: 25.391

2.  GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data.

Authors:  Sandrine Andrieu; Pierre-Jean Ousset; Nicola Coley; Mehemed Ouzid; Hélène Mathiex-Fortunet; Bruno Vellas
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Authors:  Jeffrey S Berger; Maria C Roncaglioni; Fausto Avanzini; Ierta Pangrazzi; Gianni Tognoni; David L Brown
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

4.  Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Lon S Schneider; Philip S Insel; Michael W Weiner
Journal:  Arch Neurol       Date:  2011-01

5.  Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

Authors:  L J Thal; A Carta; R Doody; P Leber; R Mohs; L Schneider; S Shimohama; C Silber
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

6.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.

Authors:  Natalia Acosta-Baena; Diego Sepulveda-Falla; Carlos Mario Lopera-Gómez; Mario César Jaramillo-Elorza; Sonia Moreno; Daniel Camilo Aguirre-Acevedo; Amanda Saldarriaga; Francisco Lopera
Journal:  Lancet Neurol       Date:  2011-02-04       Impact factor: 44.182

7.  A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics.

Authors:  Mary Sano; Diane Jacobs; Howard Andrews; Karen Bell; Neill Graff-Radford; John Lucas; Peter Rabins; Karen Bolla; Wei-Yan Tsai; Peter Cross; Karen Andrews; Rosann Costa
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

Review 8.  Methodological issues in primary prevention trials for neurodegenerative dementia.

Authors:  Sandrine Andrieu; Nicola Coley; Paul Aisen; Maria C Carrillo; Steven DeKosky; Jane Durga; Howard Fillit; Giovanni B Frisoni; Lutz Froelich; Serge Gauthier; Roy Jones; Linus Jönsson; Zaven Khachaturian; John C Morris; Jean-Marc Orgogozo; Pierre-Jean Ousset; Philippe Robert; Eric Salmon; Cristina Sampaio; Frans Verhey; Gordon Wilcock; Bruno Vellas
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

Authors:  C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh
Journal:  Neurology       Date:  2007-04-25       Impact factor: 9.910

10.  Ginkgo biloba for prevention of dementia: a randomized controlled trial.

Authors:  Steven T DeKosky; Jeff D Williamson; Annette L Fitzpatrick; Richard A Kronmal; Diane G Ives; Judith A Saxton; Oscar L Lopez; Gregory Burke; Michelle C Carlson; Linda P Fried; Lewis H Kuller; John A Robbins; Russell P Tracy; Nancy F Woolard; Leslie Dunn; Beth E Snitz; Richard L Nahin; Curt D Furberg
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272
View more
  14 in total

1.  Mindfulness, Education, and Exercise for age-related cognitive decline: Study protocol, pilot study results, and description of the baseline sample.

Authors:  Julie Loebach Wetherell; Hayley S Ripperger; Michelle Voegtle; Beau M Ances; David Balota; Emily S Bower; Colin Depp; Lisa Eyler; Erin R Foster; Denise Head; Tamara Hershey; Steven Hickman; Noralinda Kamantigue; Samuel Klein; J Philip Miller; Michael D Yingling; Jeanne Nichols; Ginger E Nicol; Bruce W Patterson; Thomas L Rodebaugh; Joshua S Shimony; Abraham Snyder; Mary Stephens; Susan Tate; Mary L Uhrich; David Wing; Gregory F Wu; Eric J Lenze
Journal:  Clin Trials       Date:  2020-06-27       Impact factor: 2.486

2.  GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies.

Authors:  Jessica B Langbaum; Jason Karlawish; J Scott Roberts; Elisabeth M Wood; Angela Bradbury; Nellie High; Trisha L Walsh; David Gordon; Raj Aggarwal; Peter Davis; Carter Stowell; Lane Trisko; Carolyn M Langlois; Eric M Reiman; Pierre N Tariot
Journal:  Alzheimers Dement       Date:  2019-02-13       Impact factor: 21.566

3.  Attitudes toward Potential Participant Registries.

Authors:  Joshua D Grill; Andrew Holbrook; Aimee Pierce; Dan Hoang; Daniel L Gillen
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Recruiting Community-Based Dementia Patients and Caregivers in a Nonpharmacologic Randomized Trial: What Works and How Much Does It Cost?

Authors:  Karen Morrison; Laraine Winter; Laura N Gitlin
Journal:  J Appl Gerontol       Date:  2014-05-04

5.  Obstacles and opportunities in Alzheimer's clinical trial recruitment.

Authors:  Jennifer L Watson; Laurie Ryan; Nina Silverberg; Vicky Cahan; Marie A Bernard
Journal:  Health Aff (Millwood)       Date:  2014-04       Impact factor: 6.301

6.  Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.

Authors:  B Vellas; H Hampel; M E Rougé-Bugat; M Grundman; S Andrieu; S Abu-Shakra; R Bateman; R Berman; R Black; M Carrillo; M Donohue; M Mintun; J Morris; R Petersen; R G Thomas; J Suhy; L Schneider; L Seely; P Tariot; J Touchon; M Weiner; C Sampaio; P Aisen
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

Review 7.  Facilitating Alzheimer disease research recruitment.

Authors:  Joshua D Grill; James E Galvin
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jan-Mar       Impact factor: 2.703

8.  The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease.

Authors:  Sarah D Tarrant; Shoshana H Bardach; Kendra Bates; Heather Nichols; Jacqueline Towner; Clay Tamatha; Allison Caban-Holt; Linda J Van-Eldik; Richard R Murphy; Reisa Sperling; Gregory A Jicha
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Apr-Jun       Impact factor: 2.703

9.  Mail and Telephone Outreach from Electronic Health Records for Research Participation on Cognitive Health and Aging.

Authors:  K Pun; C W Zhu; M T Kinsella; M Sewell; H Grossman; J Neugroschl; C Li; A Ardolino; N Velasco; M Sano
Journal:  J Prev Alzheimers Dis       Date:  2021

10.  Recruitment of a multi-site randomized controlled trial of aerobic exercise for older adults with amnestic mild cognitive impairment: The EXERT trial.

Authors:  Aladdin H Shadyab; Andrea Z LaCroix; Howard H Feldman; Christopher H van Dyck; Ozioma C Okonkwo; Steven P Tam; J Kaci Fairchild; Kathleen A Welsh-Bohmer; Genevieve Matthews; Daniel Bennett; Alexandre A Shadyab; Kimberly A Schafer; Rosemary H Morrison; Sean A Kipperman; Jennifer Mason; Donna Tan; Ronald G Thomas; Carl W Cotman; Laura D Baker
Journal:  Alzheimers Dement       Date:  2021-07-23       Impact factor: 16.655
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.